Skip to content
OpenCapital
Get started

Viridian Therapeutics, Inc. VRDN Q2 2025 earnings

Reported August 6, 2025 · Before market open

Revenue$75.0K
EPS-$1.00In line
EPS estimate-$1.00

Next report

Aug 5, 2026 (In 1 week)
Revenue estimate$30.5K
EPS estimate-$1.02

Financials

Q2 2025

Income statement

See full
Revenue$75.0K+4.2%
Operating income-$106.8M-47.9%
Net income-$100.7M-55.0%

Balance sheet

See full
Cash & equivalents$117.3M+9.0%
Total debt$23.1M+2.1%
Total equity$515.2M-2.7%
Total assets$582.3M-0.6%

Cash flow

See full
Operating cash flow-$75.4M-63.6%
CapEx$42.0K-59.6%
Free cash flow-$75.4M-63.4%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$1.2B+44.1%
Enterprise value$1.1B+47.9%
P/S3,921.8×+1,039×

Profitability

See full
Operating margin-121,831.1%+80,915pp
Net margin-112,806.9%+83,238pp
FCF margin-101,507.9%+276,805pp

Returns & leverage

See full
Return on equity-65.9%+18.7pp
Debt / equity0×0.0×
Current ratio11×-4.8×

Versus estimates

Revenue

Q1 2026$141.0KBeat by $104.9KQ4 2025$132.0KMiss by $18.2MQ3 2025$70.6MBeat by $54.8M
Q2 2025$75.0K
Q1 2025$72.0KBeat by $27.9KQ4 2024$72.0KBeat by $22.0K

Diluted EPS

Q1 2026-$0.90Beat by $0.16Q4 2025-$1.08Miss by $0.18Q3 2025-$0.34Beat by $0.48
Q2 2025-$1.00In line
Q1 2025-$0.87Beat by $0.08Q4 2024-$0.81Beat by $0.24

Ask the moment Viridian Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Viridian Therapeutics, Inc. report Q2 2025 earnings?
Viridian Therapeutics, Inc. (VRDN) reported Q2 2025 earnings on August 6, 2025 before market open.
What were Viridian Therapeutics, Inc.'s Q2 2025 revenue and EPS?
Viridian Therapeutics, Inc. reported revenue of $75.0K and eps of $-1.00 for Q2 2025.
Did Viridian Therapeutics, Inc. beat estimates in Q2 2025?
EPS beat the consensus estimate of $-1.00 by $0.00.
How did Viridian Therapeutics, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 4.2% from $72.0K a year earlier and eps grew 2.0% from $-1.02.
Where can I find Viridian Therapeutics, Inc.'s Q2 2025 SEC filings?
You can read the 10-Q periodic report (0001590750-25-000012) directly on SEC EDGAR. The filing index links above go to sec.gov.